Enveric Biosciences (ENVB) vs Traws Pharma (TRAW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Traws Pharma is the larger company by market cap ($6.8 million vs $6.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENVB | TRAW |
|---|---|---|
| Share price | $1.44 | $0.4443 |
| Market cap | $6.45M | $6.83M |
| 1-day change | -5.19% | -7.50% |
| EPS (TTM) | $-13.01 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.25 | $3.27 |
| 52-week low | $1.17 | $0.43 |
| Distance from 52-week high | -89.13% | -86.41% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +125.07% |
| Average volume | 102.84K | 569.02K |
| Shares outstanding | 4.48M | 15.37M |
| Employees | 5 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enveric Biosciences
ENVB stock →Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Traws Pharma
TRAW stock →Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
ENVB vs TRAW FAQ
Which is bigger, Enveric Biosciences or Traws Pharma?
Traws Pharma (TRAW) is larger, with a market capitalization of $6.83M compared with $6.45M for Enveric Biosciences (ENVB).
Are Enveric Biosciences and Traws Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.